In 388 patients with HR+/HER2- early breast cancer, neoadjuvant dose-dense nab-paclitaxel then epirubicin-cyclophosphamide gave a higher RCB 0/I rate than docetaxel (20.1% vs 11.34%); 5-year DFS and OS did not differ, and grade 3/4 neuropathy occurred only with nab-paclitaxel.
RCTn = 388
Zhang et al. Dose-dense neoadjuvant bi-weekly nab-paclitaxel followed by epirubicin-cyclophosphamide versus bi-weekly docetaxel followed by epirubicin-cyclophosphamide in patients with HR+/HER2- early breast cancer: a multicentre, randomised, phase III trial